Cargando…
A case of spontaneous hepatic hemangioma rupture: Successful management with transarterial chemoembolization alone
Hemangioma is the most common benign hepatic tumor. Although spontaneous rupture is rare, the mortality rate ranges from 60 to 75%. Only 34 cases have been reported in the literature, with only one report using transcatheter arterial embolization (TAE) alone as treatment. We report a case of spontan...
Autores principales: | Cao, Yanyan, Xiong, Fu, Xiong, Bin, Wang, Yong, Yuan, Feng, Ren, Yanqiao, Zheng, Chuansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562225/ https://www.ncbi.nlm.nih.gov/pubmed/34805887 http://dx.doi.org/10.1016/j.jimed.2019.09.014 |
Ejemplares similares
-
A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
por: Sun, Tao, et al.
Publicado: (2022) -
Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
por: Chen, Lei, et al.
Publicado: (2020) -
Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021) -
Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022) -
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)